Prescription drug

88 Percent Of Older Adults Want Medicare To Negotiate Drug Prices According to New Survey by The Senior Citizens League

Retrieved on: 
Tuesday, May 25, 2021
Health sciences, Health, Pharmaceuticals policy, Healthcare reform in the United States, Federal assistance in the United States, Liberalism in the United States, Medicare, Presidency of Lyndon B. Johnson, Prescription drug, Medicare Prescription Drug Price Negotiation Act, Prescription drug prices in the United States

WASHINGTON, May 25, 2021 /PRNewswire-PRWeb/ --Older Americans overwhelmingly support legislation that would allow Medicare to negotiate prescription drug prices, according to a new survey by The Senior Citizens League (TSCL) .The online survey, which had over 1,234 participants, found that 88 percent support tying prescription drug prices to what other industrialized countries, such as Great Britain, Canada and Japan, pay for the same drug.

Key Points: 
  • WASHINGTON, May 25, 2021 /PRNewswire-PRWeb/ --Older Americans overwhelmingly support legislation that would allow Medicare to negotiate prescription drug prices, according to a new survey by The Senior Citizens League (TSCL) .The online survey, which had over 1,234 participants, found that 88 percent support tying prescription drug prices to what other industrialized countries, such as Great Britain, Canada and Japan, pay for the same drug.
  • The Senior Citizens League supports legislation that would allow Medicare to negotiate drug prices, and limit drug price increases to the rate of inflation.
  • With 1.2 million supporters, The Senior Citizens League is one of the nation's largest nonpartisan seniors groups.
  • The Senior Citizens League is a proud affiliate of The Retired Enlisted Association .

Vivera Pharmaceuticals Granted Allowance for ZICOH® Patent

Retrieved on: 
Thursday, May 20, 2021
Health sciences, Health, Clinical pharmacology, Pharmacy, Prescription drug, Adherence, Opioid use disorder, Medical prescription, Medication, Opioid, Dose

b'NEWPORT BEACH, Calif., May 20, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, Inc. is pleased to announce the allowance of its dose-controlled drug delivery device patent for ZICOH.

Key Points: 
  • b'NEWPORT BEACH, Calif., May 20, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, Inc. is pleased to announce the allowance of its dose-controlled drug delivery device patent for ZICOH.
  • "\nThe ZICOH device is designed to utilize advanced biometric technology to ensure only authorized access to the medication within the specialized cartridge is granted.
  • With a software backbone that allows for real-time monitoring of patient compliance with provider orders, the ZICOH ecosystem can be used with any prescription medication.
  • Vivera is looking forward to collaborating with Medical Device and Pharmaceutical manufacturers as we collectively work to reduce opioid addiction.

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

Retrieved on: 
Thursday, May 20, 2021
Health sciences, Health, Medicine, Leukopenia, Breastfeeding, Complete blood count, Prescription drug, HIV and pregnancy, Neonatal sepsis

Your doctor will monitor your blood counts during treatment with VYXEOS.

Key Points: 
  • Your doctor will monitor your blood counts during treatment with VYXEOS.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
  • Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA.
  • Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death.

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

Retrieved on: 
Thursday, May 20, 2021
Health sciences, Health, Medicine, Leukopenia, Breastfeeding, Complete blood count, Prescription drug, HIV and pregnancy, Neonatal sepsis

Your doctor will monitor your blood counts during treatment with VYXEOS.

Key Points: 
  • Your doctor will monitor your blood counts during treatment with VYXEOS.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
  • Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA.
  • Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death.

Navitus Health Solutions Earns 2021 Pharmacy Quality Alliance Award for High Achievement in Medication Quality Measures

Retrieved on: 
Tuesday, May 18, 2021
General Health, Diabetes, Health, Pharmaceutical, Managed care, Health sciences, Health, Clinical pharmacology, Pharmacy, Symbols, Medical terminology, Pharmaceuticals policy, Pharmacy benefit management, Adherence, Prescription drug, Medicare, Medical prescription

b'Navitus Health Solutions, a full pass-through pharmacy benefit manager (PBM), today announced that it received the 2021 Pharmacy Quality Alliance (PQA) Laura Cranston Excellence in Quality Award for its prescription drug plan (PDP), Navitus MedicareRx.

Key Points: 
  • b'Navitus Health Solutions, a full pass-through pharmacy benefit manager (PBM), today announced that it received the 2021 Pharmacy Quality Alliance (PQA) Laura Cranston Excellence in Quality Award for its prescription drug plan (PDP), Navitus MedicareRx.
  • Navitus is one of nine healthcare organizations to receive PQA\xe2\x80\x99s Excellence in Quality Award for PDPs this year.
  • However, medication non-adherence is a longstanding issue in the United States.
  • As such, Navitus is committed to taking the unnecessary costs out of pharmacy benefits to make prescriptions more affordable for hundreds of plan sponsors (i.e., employers, health plans, unions, government programs, etc.)

Interim Report Q1, 2021

Retrieved on: 
Tuesday, May 18, 2021
Pharmaceuticals policy, Health, Food and Drug Administration, Prescription Drug User Fee Act, Prescription drug

The FDA have set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.

Key Points: 
  • The FDA have set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.
  • "\nNo net sales for the three months ended March 31, 2021 were recognized.
  • The FDA have set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.
  • Subject to approval, this would enable commercialization of Nefecon in the US in Q4, 2021.\nInterim Report for the period January 1 June 30, 2021 August 19, 2021\nInterim Report for the period January 1 September 30, 2021 November 18, 2021\nYear-end Report for the period January 1 December 31, 2021 February 24, 2022\n'

Interim Report Q1, 2021

Retrieved on: 
Tuesday, May 18, 2021
Pharmaceuticals policy, Health, Food and Drug Administration, Prescription Drug User Fee Act, Prescription drug

The FDA have set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.

Key Points: 
  • The FDA have set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.
  • "\nNo net sales for the three months ended March 31, 2021 were recognized.
  • The FDA have set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.
  • Subject to approval, this would enable commercialization of Nefecon in the US in Q4, 2021.\nInterim Report for the period January 1 June 30, 2021 August 19, 2021\nInterim Report for the period January 1 September 30, 2021 November 18, 2021\nYear-end Report for the period January 1 December 31, 2021 February 24, 2022\n'

Procaps Group Reports Record First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021
Medical devices, Medical Supplies, Hospitals, Finance, Diabetes, Professional services, Biotechnology, General Health, Pharmaceutical, Health, Pharmaceuticals policy, Health sciences, Health, Drugs, Clinical pharmacology, Pharmacy, Prescription drug, Over-the-counter drug, Earnings before interest, taxes, depreciation and amortization, Dietary supplement, the Business Combination with Union Acquisition Corp. II, Procaps Group, Union Acquisition Corp. II., THE BUSINESS COMBINATION WITH UNION ACQUISITION CORP. II, PROCAPS GROUP, UNION ACQUISITION CORP. II.

Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.

Key Points: 
  • Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.
  • Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model.
  • Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.
  • A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements.

TroyRx Delivers More Prescription Savings and Options to Patients Through Partnership with RxSense

Retrieved on: 
Thursday, May 13, 2021
Symbols, Health sciences, Health, Clinical pharmacology, Articles, Pharmaceuticals policy, Medical prescription, Patient safety, Pharmacy, Prescription drug

b'CANONSBURG, Pa., May 13, 2021 /PRNewswire-PRWeb/ --TroyRx, an industry leader in prescription software solutions, today announces a partnership with RxSense, the healthcare technology company improving transparency and access to affordable medications.

Key Points: 
  • b'CANONSBURG, Pa., May 13, 2021 /PRNewswire-PRWeb/ --TroyRx, an industry leader in prescription software solutions, today announces a partnership with RxSense, the healthcare technology company improving transparency and access to affordable medications.
  • RxSense\'s technology will help to power TroyRx\'s prescription discount card, OptionRx and enable consumers and patients to save up to 80% on their prescriptions at thousands of retail pharmacies nationwide.
  • Available in both printed and digital formats, OptionRx savings help inform uninsured and underinsured patients of their best affordability options.
  • "Our new partnership with RxSense grows our patient centric network infrastructure, increases the value it can bring to more patients, and improves the prescription experience for providers and their patients on complex therapies.

Covanta Assists Local Connecticut Law Enforcement on National Prescription Drug Take Back Day

Retrieved on: 
Thursday, May 13, 2021
Articles, Health sciences, Health, Medical waste, Covanta, Occupational safety and health, Water conservation, Waste, Prescription drug, Electronic waste, Recycling, Drug disposal

To combat this alarming fact, Covanta, a state leader in sustainable waste disposal partnered with local law enforcement in Bristol, West Hartford, Meriden and Berlin, Connecticut to collect unwanted and expired medications in honor of the DEA\'s National Prescription Drug Take Back Day .

Key Points: 
  • To combat this alarming fact, Covanta, a state leader in sustainable waste disposal partnered with local law enforcement in Bristol, West Hartford, Meriden and Berlin, Connecticut to collect unwanted and expired medications in honor of the DEA\'s National Prescription Drug Take Back Day .
  • We\'re proud to partner with local law enforcement and have our waste-to-energy facilities play a critical role in this very important initiative.
  • "\nCovanta has been providing safe disposal of medications collected at community-sponsored, drug take-back programs for over ten years, working with local and federal law enforcement.
  • With a nationwide network of treatment, recycling and Waste-to-Energy facilities, Covanta Environmental Solutions enables customers to mitigate risk and reach their sustainability goals.